E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020603 |
E.1.2 | Term | Hypercholesterolaemia |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of alirocumab administered every 2 weeks (Q2W) and every 4 weeks (Q4W) versus placebo after 24 weeks of double-blind (DB) treatment on low-density lipoprotein cholesterol (LDL-C) levels in patients with heterozygous familial hypercholesterolemia (heFH) 8 to 17 years of age on optimal
stable daily dose of statin therapy ± other lipid modifying therapies (LMTs) or a stable dose of nonstatin LMTs in case of intolerance to statins. |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the efficacy of alirocumab versus placebo on low-density lipoprotein cholesterol (LDL-C) levels.
-To evaluate the effects of alirocumab versus placebo on other lipid parameters.
-To evaluate the safety and tolerability of alirocumab in comparison with placebo.
-To evaluate the efficacy, safety, and tolerability of alirocumab after open label treatment.
-To evaluate the development of anti-alirocumab antibodies. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A non-invasive flow mediated dilatation assessment will be part of a substudy (n=30 to 39) performed at selected sites. |
|
E.3 | Principal inclusion criteria |
-Children and adolescent male and female patients aged 8 to 17 years at the time of signed informed consent.
-Patients with diagnosis of heterozygous familial hypercholesterolemia (heFH) through genotyping or clinical criteria.
-Patients treated with optimal dose of statin +/- other LMT(s) or non-statin LMT(s) if statin intolerant at stable dose for at least 4 weeks prior to screening lipid sampling.
-Patients with calculated LDL-C greater than or equal to 130 mg/dL (≥3.37 mmol/L) at the screening visit except for patients who have previously participated in the DFI14223 study.
-A signed informed consent indicating parental permission with or without patient assent. |
|
E.4 | Principal exclusion criteria |
-Patient with body weight less than 25 kg.
-Patients aged of 8 to 9 years not at Tanner stage 1 and patients aged of 10 to 17 years not at least at Tanner stage 2 in their development.
-Patients with secondary hyperlipidemia.
-Diagnosis of homozygous familial hypercholesterolemia.
-Patient who has received lipid apheresis treatment within 2 months prior to the screening period, or has plans to receive it during the study.
-Patients with uncontrolled type 1 or type 2 diabetes mellitus.
-Patients with known uncontrolled thyroid disease.
-Patients with uncontrolled hypertension.
-Fasting triglycerides >350 mg/dL (3.95 mmol/L).
-Severe renal impairment (ie, estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m^2.
-Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 x upper limit of normal (ULN).
-Creatinine phosphokinase (CPK) >3 x ULN. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percent change in low-density lipoprotein cholesterol (LDL-C): Percent change in LDL-C from baseline to Week 24 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) Percent change in LDL-C: Percent change in LDL-C
2) Percent change in Apo B: Percent change in Apo B
3) Percent change in non-high density lipoprotein cholesterol (non HDL-C): Percent change in non-HDL-C
4) Percent change in Total-C: Percent change in Total-C
5) Patients with LDL-C level <130 mg/dL (3.37 mmol/L): Proportion of patients with LDL-C level < 130 mg/dL (3.37 mmol/L) at Week 12 and at Week 24
6) Patients with LDL-C level <110 mg/dL (2.84 mmol/L): Proportion of patients with LDL-C level < 110 mg/dL (2.84 mmol/L) at Week 12 and at Week 24
7) Percent change in Lp(a): Percent change in lipoprotein (a) from baseline to Week 12 and to Week 24
8) Percent change in HDL-C: Percent change in HDL-C from baseline to Week 12 and to Week 24
9) Percent change in TG: Percent change in fasting triglycerides (TG) from baseline to Week 12 and to Week 24
10) Percent change in Apo A-1: Percent change in apolipoprotein A1 (Apo A-1) from baseline to Week 12 and to Week 24
11) Number of patients with adverse events: Number of patients with adverse events
12) Cogstate battery test: The Cogstate battery test will assess maturing cognition across a broad number of key developmental functions
13) Tanner stage: The Tanner stages will be measured to assess stages of pubertal development |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) From baseline to Week 12
2) to 10) From baseline to Week 12 and to Week 24
11) Up to Week 104
12) A Day 1, Weeks 24, 68, and 104
13) At Weeks 24, 44, 68, and 104 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Lebanon |
Mexico |
Russian Federation |
South Africa |
Taiwan |
Turkey |
United States |
Austria |
Bulgaria |
Czechia |
Denmark |
Finland |
France |
Germany |
Hungary |
Italy |
Netherlands |
Norway |
Poland |
Spain |
Sweden |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |